

ASX / MEDIA ANNOUNCEMENT

20<sup>th</sup> May 2013

**LETTER OF INTENT SIGNED  
WITH A MAJOR MEDICAL PRODUCTS DISTRIBUTOR IN TAIWAN**

Analytica (ASX:ALT) is pleased to announce that it has secured a letter of intent from a major medical products distributor in Taiwan - Taiwan Allied Dragon Inc (TAD)

This should lead to the Analytica Auto Start Burette being rolled out initially in Taiwan and then into other Asian markets.

Taiwan Allied Dragon's CEO, Mr Cotch Liao, stated: "Analytica's AutoStart Burette is in a category of its own and makes a lot of sense for hospitals in Taiwan and the Greater China Region. We are excited to have the opportunity to distribute this innovative technology, helping our hospitals and clinics to be more productive, efficient and safer. We see a very bright future for Analytica and their technologies in Taiwan and the broader region."

**About the Market**

Taiwan, consists of a market of 23 million people with a gross domestic product (GDP) of USD467 million, with a GDP per capita of USD37,000 similar to Australia USD39,000 . Taiwan has weathered the recent financial crisis in good form and is expected to have a GDP growth of over 4% in 2013. The medical system consists of over 507 hospitals (approximately 90% private) and 20,628 clinics representing approximately 180,000 beds. With a strong health system, 6.9 beds per 1000 population (global average 4.3 beds per 1000 population), the required characteristics are present for the Auto Start Burette's successful market penetration.

**About Taiwan Allied Dragon Inc**

Established in 2002 TAD has a strong knowledge of the health market through ownership of hospitals and the manufacture and export of medical technologies. Involvement in the health sector, as hospital stakeholders, gives them access to a range of decision makers in the Health Ministry, National and Private Hospital networks.

**Next Steps**

Legal documentation to formalize the relationship is underway. TAD will manage the regulatory approval for the Auto Start Burette in the ensuing months and will undergo trials at local hospitals as part of the market entry process.

This opportunity is the first result of the initiative announced to the market on the 21<sup>st</sup> February 2013 where Analytica engaged South-South Capital Partners to take our AutoStart Burette technology into Indonesia, Malaysia, The Philippines, Singapore, Taiwan and Thailand..

For, and on behalf of the board,

**Dr Michael Monsour**

Chairman, Board of Directors

*About Analytica Limited (ASX:ALT)*

*Analytica is an Australian company dedicated to the design, development and supply of a range of Class I and IIa medical devices.*

*About South-South Capital Partners*

*South-South Capital Partners (SSCP) is a boutique international trade and investment consulting firm specializing in bringing emerging technologies to emerging markets, specifically South America and South East Asia. More information can be found at the website: [www.south-southcapital.com](http://www.south-southcapital.com)*

